



Correction

Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. *Curr. Oncol.* 2023, 30, 6097–6110

Alberto Alvarado-Miranda ¹, Fernando Ulises Lara-Medina ¹, Wendy R. Muñoz-Montaño ¹ , Juan W. Zinser-Sierra ², Paula Anel Cabrera Galeana ¹, Cynthia Villarreal Garza ³, Daniel Sanchez Benitez ¹, Jesús Alberto Limón Rodríguez ⁴, Claudia Haydee Arce Salinas ¹, Alberto Guijosa ⁵ and Oscar Arrieta ^{6,*} 

- ¹ Breast Tumors Unit, Instituto Nacional de Cancerología, Mexico City 14080, Mexico
² Gastrointestinal Oncology Unit, Instituto Nacional de Cancerología, Mexico City 14080, Mexico
³ Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnológico de Monterrey, San Pedro Garza García 66278, Mexico; cynthia.villarreal@tecsalud.mx
⁴ Grupo Opción Oncología, Monterrey 64060, Mexico
⁵ School of Medicine, Universidad Panamericana, Mexico City 03920, Mexico
⁶ Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico
 * Correspondence: ogar@unam.mx; Tel.: +52-55-5628-0400 (ext. 71101)



Citation: Alvarado-Miranda, A.; Lara-Medina, F.U.; Muñoz-Montaño, W.R.; Zinser-Sierra, J.W.; Galeana, P.A.C.; Garza, C.V.; Sanchez Benitez, D.; Limón Rodríguez, J.A.; Arce Salinas, C.H.; Guijosa, A.; et al. Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. *Curr. Oncol.* 2023, 30, 6097–6110. *Curr. Oncol.* 2024, 31, 7177–7179. <https://doi.org/10.3390/curroncol31110529>

Received: 14 October 2024

Revised: 30 October 2024

Accepted: 6 November 2024

Published: 15 November 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

In the original publication [1], there was a mistake in Table 2 as published. The original Table 2 considered different amounts of patients for the survival analysis at the data cut-off. The corrected Table 2 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Table 2. Univariate and multivariate analyses of factors associated with overall survival. XELIA: capecitabine and aromatase inhibitor; HT: hormone therapy (aromatase inhibitor); CTx: chemotherapy (capecitabine); ECOG PS: Eastern Cooperative Oncology Group Performance Status; SBR: Scarff–Bloom–Richardson; ER: estrogen receptor; PgR: progesterone receptor; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; BCS: breast conservation surgery; MRM: modified radical mastectomy; X: median not reached; * regardless of affected site. Statistically significant *p*-values are shown in bold.

	Total (Events)	Median (95% CI)	<i>p</i> -Value	HR (95% CI)	<i>p</i> -Value
ECOG PS					
0–1	136 (62)	42.9 (31.1–54.7)	0.972		
≥2	27 (15)	63.4 (33.9–92.8)			
Hormonal status					
Pre- or peri-menopausal	54 (19)	46.5 (27.2–65.8)	0.199		
Postmenopausal	109 (58)	52.3 (34.5–70.2)			
Tumor status					
≤T2	62 (25)	62.4 (48.5–76.3)	0.547		
T3	40 (21)	40.9 (30.7–51.1)			
T4	61 (31)	41.8 (25.6–58.1)			

Table 2. Cont.

	Total (Events)	Median (95% CI)	p-Value	HR (95% CI)	p-Value
Nodal status					
N0	24 (9)	65.6 (29.7–101.4)	0.707		
N1	59 (27)	44.9 (36.7–53.2)			
N2	51 (25)	42.3 (33.4–51.1)			
N3	29 (16)	52.8 (25.7–79.9)			
Disease state					
Recurrent disease	131 (61)	46.5 (33.1–60.0)	0.947		
Metastatic disease	32 (16)	47.9 (16.2–79.7)			
Histological subtype					
IDC	135 (63)	52.8 (35.5–70.1)	0.884		
ILC	28 (14)	37.4 (26.4–48.3)			
Ki67					
<20	46 (17)	62.39 (27.7–97.1)	0.507		
≥20	50 (24)	46.5 (21.7–71.4)			
Unknown	67 (36)	52.3 (32.2–72.5)			
SBR					
Low	13 (5)	80.1 (31.7–128.6)	0.085		
Intermediate and high	130 (66)	40.0 (34.3–47.5)			
Unknown	20 (6)	63.4 (42.4–84.4)			
ER					
Negative	7 (4)	18.1 (17.8–18.5)	0.451		
Positive	156 (73)	47.9 (40.1–64.5)			
PgR					
Negative	32 (17)	34.3 (11.5–57.3)	0.447		
Positive	131 (60)	47.9 (28.1–67.8)			
ER/PgR					
ER+, PgR+	124 (56)	52.3 (32.6–72.1)	0.533		
ER+, PgR–	32 (17)	34.4 (11.5–57.3)			
ER–, PgR+	7 (4)	18.1 (17.8–18.5)			
Type of surgery					
BCS	17 (5)	98.9 (8.5–189.4)	0.387		
MRM	121 (61)	44.9 (34.7–55.2)			
None	25 (11)	36.3 (0–79.57)			
Adjuvant endocrine Therapy					
Tamoxifen	57 (26)	52.3 (29.6–75.1)	0.748		
Aromatase inhibitors	106 (51)	42.8 (26.9–58.8)			
Disease-free interval % (n/N)					
Newly metastatic disease	32 (16)	47.9 (16.6–79.7)	0.993		
≤24 months	40 (18)	46.5 (24.3–68.7)			
>24 months	91 (43)	44.9 (30.2–59.7)			
Number of metastases % (n/N)					
1 place	105 (47)	53.5 (34.9–72.1)	0.010	1.129 (0.879–1.449)	0.341
2 places	36 (22)	34.4 (30.0–47.8)			
≥3 places	12 (6)	26.4 (9.5–43.3)			
CNS involvement *	10 (2)	X			
Disease site % (n/N)					
Visceral	84 (40)	40.4 (21.4–59.4)	0.068		
Non-visceral	16 (3)	X			
Bone	63 (34)	44.4 (37.3–52.6)			
Treatment					
XELIA	95 (45)	53.5 (30.3–76.6)	0.122	1.262 (0.947–1.683)	0.112
Hormone therapy	35 (15)	47.9 (24.6–71.2)			
Chemotherapy	33 (17)	40.4 (34.7–61.3)			

Reference

1. Alvarado-Miranda, A.; Lara-Medina, F.U.; Muñoz-Montaño, W.R.; Zinser-Sierra, J.W.; Galeana, P.A.C.; Garza, C.V.; Sanchez Benitez, D.; Limón Rodríguez, J.A.; Arce Salinas, C.H.; Guijosa, A.; et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. *Curr. Oncol.* **2023**, *30*, 6097–6110. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.